State of the Art in Nuclear Medicine Dose Assessment

Seminars in Nuclear Medicine

Volumn 38, Issue 5, 2008, Pages 308-320

  Stabin, Michael G ^a   Brill, A Bertrand ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLTRYOSINE OCTREOTIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTIDE; BEXXAR I 131; DIAGNOSTIC AGENT; OCTREOTHER Y 90; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SODIUM IODINE I 124; UNCLASSIFIED DRUG; ZEVALIN Y 90;

BONE; BONE MARROW; BONE MARROW TOXICITY; BRACHYTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; CORRELATION ANALYSIS; DOSIMETRY; GRAVES DISEASE; HUMAN; MATHEMATICAL COMPUTING; NEUROBLASTOMA; NUCLEAR MEDICINE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER; THYROID DISEASE;

ALGORITHMS; BODY BURDEN; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; NUCLEAR MEDICINE; RADIOISOTOPES; RADIOMETRY; RELATIVE BIOLOGICAL EFFECTIVENESS;

EID: 47749129217     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2008.05.005     Document Type: Review

References (115)

1. Marinelli L., Quimby E., and Hine G. Dosage determination with radioactive isotopes II, practical considerations in therapy and protection. Am J Roent Radium Ther 59 (1948) 260-280
2. Quimby E., and Feitelberg S. Radioactive Isotopes in Medicine and Biology (1963), Lea and Febiger, Philadelphia
3. Loevinger R., Budinger T., and Watson E. MIRD Primer for Absorbed Dose Calculations (1988), Society of Nuclear Medicine, Reston, VA
4. Stabin M.G., and Siegel J.A. Physical models and dose factors for use in internal dose assessment. Health Phys 85 (2003) 294-310
5. International Commission on Radiological Protection. 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60 (1991), Pergamon Press, New York
6. Snyder W., Ford M., Warner G., et al. MIRD Pamphlet No 5 - Estimates of Absorbed Fractions for Monoenergetic Photon Sources Uniformly Distributed in Various Organs of a Heterogeneous Phantom. J Nucl Med Suppl 3 (1969) 5
7. International Commission on Radiological Protection. ICRP Publication 23, Task Group Report on Reference Man (1975), Pergamon Press, Oxford
8. International Commission on Radiological Protection. ICRP Publication 89: Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values (2003), Elsevier Health, New York
9. Snyder W., Ford M., and Warner G. Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom. MIRD Pamphlet No. 5, revised (1978), Society of Nuclear Medicine, New York
10. Snyder W., Ford M., Warner G., et al. A Tabulation of Dose Equivalent Per Microcurie-Day for Source and Target Organs of an Adult for Various Radionuclides. ORNL-5000 (1975), Oak Ridge National Laboratory, Oak Ridge, TN
11. Cristy M., and Eckerman K. Specific Absorbed Fractions of Energy at Various Ages From Internal Photons Sources. ORNL/TM-8381 V1-V7 (1987), Oak Ridge National Laboratory, Oak Ridge, TN
12. Stabin M. MIRDOSE: The personal computer software for use in internal dose assessment in nuclear medicine. J Nucl Med 37 (1996) 538-546
13. Stabin M.G., Sparks R.B., and Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46 (2005) 1023-1027
14. Stabin M., Watson E., Cristy M., et al. Mathematical models and specific absorbed fractions of photon energy in the nonpregnant adult female and at the end of each trimester of pregnancy. ORNL Report ORNL/TM-12907 (1995)
15. Segars J.P. Development and Application of the New Dynamic NURBS-based Cardiac-Torso (NCAT) Phantom, PhD Dissertation, The University of North Carolina (2001)
16. Spiers F.W. Beta dosimetry in trabecular bone. In: Mays C.W. (Ed). Delayed Effects of Bone-Seeking Radionuclides (1969), University of Utah Press, Salt Lake City, UT 95-108
17. Eckerman K., and Stabin M. Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal regions. Health Phys 78 (2000) 199-214
18. Bouchet L.G., Bolch W.E., Howell R.W., et al. S-Values for radionuclides localized within the skeleton. J Nucl Med 41 (2000) 189-212
19. Stabin M.G., Eckerman K.F., Bolch W.E., et al. Evolution and status of bone and marrow dose models. Cancer Biother Radiopharm 17 (2002) 427-434
20. Shah A.P., Bolch W.E., Rajon D.A., et al. A paired-image radiation transport model for skeletal dosimetry. J Nucl Med 46 (2005) 344-353
21. Siegel J., Thomas S., Stubbs J., et al. MIRD Pamphlet No 16-Techniques for Quantitative Radiopharmaceutical Biodistribution Data Acquisition and Analysis for Use in Human Radiation Dose Estimates. J Nucl Med 40 (1999) 37S-61S
22. Ogawa K., Harata Y., Ichihara T., et al. A practical method for position-dependent Compton-scatter correction in single emission CT. IEEE Trans Medimag 10 (1991) 408-412
23. King M., and Farncombe T. An overview of attenuation and scatter correction of planar and SPECT data for dosimetry studies. Cancer Biother Radiopharm 18 (2003) 181-190
24. Autret D., Bitar A., Ferrer L., et al. Monte Carlo modeling of gamma cameras for I-131 imaging in targeted radiotherapy. Cancer Biother Radiopharm 20 (2005) 77-84
25. Dewaraja Y.K., Wilderman S.J., Ljungberg M., et al. Accurate dosimetry in I-131 radionuclide therapy using patient- specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. J Nucl Med 46 (2005) 840-849
26. 131I-19-iodocholesterol: The pitfalls of using tissue concentration data, the author's reply. J Nucl Med 16 (1975) 248-249
27. 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45 (2004) 1366-1372
28. International Commission on Radiological Protection. ICRP Publication 53: Radiation Dose to Patients from Radiopharmaceuticals, 53 (1989), Pergamon, New York
29. International Commission on Radiological Protection. Radiation Dose to Patients from Radiopharmaceuticals. ICRP Publication 80 (2000), Pergamon, New York
30. Snyder W. Estimates of absorbed fraction of energy from photon sources in body organs. Medical Radionuclides: Radiation Dose and Effects (1970), USAEC 33-50
31. Hindorf C., Linden O., Stenberg L., et al. Change in tumor absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients. Clin Cancer Res 9 (2003) 4003s-4006s
32. Siegel J.A., and Stabin M.G. Mass-scaling of S Values for blood-based estimation of red marrow absorbed dose: The quest for an appropriate method. J Nucl Med 48 (2007) 253-256
33. Traino A.C., and Di Martino F.A. Dosimetric algorithm for patient-specific 131I therapy of thyroid cancer based on a prescribed target-mass reduction. Phys Med Biol 51 (2006) 6449-6456
34. Hartman Siantar C.L. Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy. J Nucl Med 44 (2003) 1322-1329
35. Traino A.C., Ferrari M., Cremonesi M., et al. Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry. Phys Med Biol 52 (2007) 5231-5248
36. Stabin MG, Stubbs JB, Toohey RE: Radiation Dose Estimates for Radiopharmaceuticals. NUREG/CR-6345, prepared for: US Nuclear Regulatory Commission, US Department of Energy, US Department of Health & Human Services, 81 pages, 1996
37. International Commission on Radiological Protection. Radiation Dose Estimates for Radiopharmaceuticals. ICRP Publications 53 and 80, with addenda (1983), Pergamon Press, New York 1991
38. Kolbert K.S., Sgouros G., Scott A.M., et al. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med 38 (1997) 301-308
39. Dewaraja Y.K., Wilderman S.J., Ljungberg M., et al. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. J Nucl Med 46 (2005) 840-849
40. Liu A., Williams L., Lopatin G., et al. A radionuclide therapy treatment planning and dose estimation system. J Nucl Med 40 (1999) 1151-1153
41. Guy M.J., Flux G.D., Papavasileiou P., et al. RMDP: A dedicated package for I-131 SPECT quantification, registration and patient-specific dosimetry. Cancer Biother Radiopharm 18 (2003) 61-69
42. Clairand I., Ricard M., Gouriou J., et al. DOSE3D: EGS4 Monte Carlo code-based software for internal radionuclide dosimetry. J Nucl Med 40 (1999) 1517-1523
43. Bielajew A., and Rogers D. PRESTA: The parameter reduced electron-step transport algorithm for electron monte carlo transport. Nucl Instrum Methods B18 (1987) 165-181
44. Briesmeister JF (ed): "MCNP-A General Monte Carlo N-Particle Transport Code, Version 4C," LA-13709-M, Los Alamos National Laboratory April 2000
45. Allison J., Amako K., Apostolakis J., et al. Geant4 developments and applications. IEEE Trans Nucl Sci 53 (2006) 270-278
46. Lehmann J., Hartmann Siantar C., et al. Monte Carlo treatment planning for molecular targeted radiotherapy within the MINERVA system. Phys Med Biol 50 (2005) 947-958
47. Sgouros G., Kolbert K.S., Sheikh A., et al. Larson patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45 (2004) 1366-1372
48. DeNardo D.A., DeNardo G.L., O'Donnell R.T., et al. Imaging for improved prediction of myelotoxicity after radioimmunotherapy. Cancer 80 (1997) 2558-2566
49. Siegel J.A., Lee R.E., Pawlyk D.A., et al. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int J Rad Appl Instrum (B) 16 (1989) 553-559
50. Siegel J.A., Wessels B.W., Watson E.E., et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharmacol 3 (1990) 213-233
51. Lim S.-M., DeNardo G.L., DeNardo D.A., et al. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. J Nucl Med 38 (1997) 1474-1378
52. Breitz H., Fisher D., and Wessels B. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monocolonal antibody. J Nucl Med 39 (1998) 1746-1751
53. Eary J.F., Krohn K.A., Press O.W.Q., et al. Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non Hodgkin's lymphoma. Nucl Med Biol 24 (1997) 635-638
54. 1. Dependence on red marrow dosimetry and pretreatment.in sixth international radiopharmaceutical dosimetry symposium Vol I (Jan 1999) 113-125 Proceedings of May 7-10, 1996 Gatlinburg, TN, Symposium, ORAU
55. Juweid M.E., Zhang C.-H., Blumenthal R.D., et al. Prediction of hematologic toxicity after radioimmunotherapy with 131I-labeled anticarcinoembryoinic antigen monoclonal antibodies. J Nuc Med 10 (1999) 1609-1616
56. Wiseman G.A., Kornmehl E., Leigh B., et al. Radiation Dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J Nucl Med 44 (2003) 465-474
57. Shen S., Meredith R.F., Duan J., et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting 90Y-antibody therapy. J Nucl Med 43 (2002) 1245-1253
58. Siegel J.A., Yeldell D., Goldenberg D.M., et al. Red marrow radiation dose adjustment using plasma FLT3-l cytokine levels: Improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med 44 (2003) 67-76
59. 90Y-labeled somatostatin analogs. J Nucl Med 46 (2005) 92S-98S (suppl)
60. Kobe C., Eschner W., Sudbrock F., et al. Graves' disease and radioiodine therapy: Is success of ablation dependent on the achieved dose above 200 Gy?. Nuklearmedizin 47 (2008) 13-17
61. Smith R.N., and Wilson G.M. Clinical trial of different doses of 131I in treatment of thyrotoxicosis. Br Med J 1 (1967) 129-132
62. Becker D.V., McConahey W.M., Dobyns B.M., et al. The results of radioiodine treatment of hyperthyroidism. In: Fellinger K., and Höfer R. (Eds). Further Advances in Thyroid Research (1971), Verlage der wiener Medizinischen Akademie, Vienna, Austria 603-609
63. Dale R., and Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm 20 (2005) 47-51
64. Bodey R.K., Flux G.D., and Evans P.M. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm 18 (2003) 89-97
65. Barone R., Borson-Chazot F., Valkema R., et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 46 (2005) 99S-106S
66. Dale R.G. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 58 (1985) 515
67. Sachs R.K., Hahnfeld P., and Brenner D.J. The link between low-LET dose-response relations and the underlying kinetics of damage production/repair/misrepair. Int J Radiat Biol 72 (1997) 351-374
68. Lea D.E., and Catcheside D.G. The mechanism of the induction by radiation of chromosome abberations in Tradescantia. J Genet 44 (1942) 216-245
69. Barendson G.W. Dose fractionation, dose-rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 8 (1982) 1981-1987
70. Fowler J.F. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62 (1989) 679-694
71. Malaroda A., Flux G.D., Buffa F.M., et al. Multicellular dosimetry in voxel geometry for targeted radionuclide therapy. Cancer Biother Radiopharm 18 (2003) 451-461
72. O'Donoghue J.A., Sgouros G., Divgi C.R., et al. Single-dose versus fractionated radioimmunotherapy: Model comparisons for uniform tumor dosimetry. J Nucl Med 41 (2000) 538-547
73. Prideaux A.R., Song H., Hobbs R.F., et al. Three-dimensional radiobiologic dosimetry: Application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med 48 (2007) 1008-1016
74. Bodey R.K., Evans P.M., and Flux G.D. Application of the linear-quadratic model to combined modality radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 228-241
75. Hall E.J. The bystander effect. Health Phys 85 (2003) 31-35
76. Khan M.A., Hill R.P., and Van Dyk J. Partial volume rat lung irradiation: An evaluation of early DNA damage. Int J Radiat Oncol Biol Phys 40 (1998) 467/76
77. Sgouros G., Knox S.J., Joiner M.C., et al. MIRD continuing education: Bystander and low-dose-rate effects: Are these relevant to radionuclide therapy?. J Nucl Med 48 (2007) 1683-1691
78. Wessels B.W., Bolch W.E., Bouchet L.G., et al., American Association of Physicists in Medicine. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: A multiinstitutional comparison. J Nucl Med 45 (2004) 1725-1733
79. Eschmann S.M., Reischl G., Bilger K., et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 29 (2002) 760-767
80. Canzi C., Zito F., Voltini F., et al. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients. Med Phys 33 (2006) 2860-2867
81. Carlier T., Salaun P.Y., Cavarec M.B., et al. Optimized radioiodine therapy for Graves' disease: Two MIRD-based models for the computation of patient-specific therapeutic I-131 activity. Nucl Med Commun 27 (2006) 559-566
82. Smith R.N. Clinical trial of different doses of 131I in the treatment of thyrotoxicosis. Br Med J 1 (1967) 129-131
83. Grosso M., Traino A., Boni G., et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism. Cancer Biother Radiopharm 20 (2005) 218-223
84. Furhang E.E., Larson S.M., Buranapong P., et al. Thyroid cancer dosimetry using clearance fitting. J Nucl Med 40 (1999) 131-136
85. Maxon H.R., Thomas S.R., and Samaratunga R.C. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid 7 (1997) 183-187
86. Reiners C. Radioiodine therapy of thyroid cancer. Tumordiagnostik Therapie 19 (1998) 70-73
87. Benua S., Cicale N.R., Sonenberg M., et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 87 (1962) 171-182
88. Ott R.J., Tait D., Flower M.A., et al. Treatment Planning for I-131 metaiodobenzylguanidine radiotherapy of neural crest tumors using I-124 metaiodobenzylguanidine positron emission tomography. Br J Radiol 65 (1992) 787-791
89. Sgouros G., Kolbert K.S., Sheikh A., et al. Patient-specific dosimetry for I-131 thyroid cancer therapy using I-124 PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45 (2004) 1366-1372
90. Dorn R., Kopp J., Vogt H., et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: Largest safe dose using a risk-adapted approach. J Nucl Med 44 (2003) 451-456
91. Hanscheid H., Lassmann M., Luster M., et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: Procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47 (2006) 648-654
92. Lassman M., Luste M., Hanschei H., et al. Impact of I-131 diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 45 (2004) 619-625
93. Sisson J.C., Avram A.M., Lawson S.A., et al. The so-called stunning of thyroid tissue. J Nucl Med 47 (2006) 1406-1412
94. Woolfenden J.M. Thyroid stunning revisited. J Nucl Med 47 (2006) 1403-1405
95. Oyen W.J.G., Bodei L., Giammarile F., et al. Targeted therapy in nuclear medicine-current status and future prospects. Ann Oncol 18 (2007) 1782-1792
96. Ron E., Doody M.M., Becker D.V., et al., Cooperative Thyrotoxicosis Therapy Follow-up Study Group. Cancer mortality following treatment for adult hyperthyroidism. JAMA 280 (1998) 347-355
97. Hoefnagel C.A. Nuclear medicine therapy of neuroblastoma. Q J Nucl Med 43 (1999) 336-343
98. Matthay K.K., Panina C., Huberty J., et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with I-131-MIBG. J Nucl Med 42 (2001) 1713-1721
99. Gaze M.N., Chang Y.C., Flux G.D., et al. Feasibility of dosimetry-based high-dose I-131-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biotherapy Radiopharm 20 (2005) 195-199
100. Monsieurs M., Brans B., Bacher K., et al. Patient dosimetry for I-131-MIBG therapy for neuroendocrine tumours based on I-123-MIBG scans. Eur J Nucl Med Mol Imaging 29 (2002) 1581-1587
101. Flux G.D., Guy M.J., Papavasileiou P., et al. Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG. Cancer Biother Radiopharm 18 (2003) 81-87
102. Garber K. Users fear that lymphoma drugs will disappear. J Natl Cancer Inst 99 (2007) 498-501
103. Wiseman G.A., White C.A., Sparks R.B., et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin (TM) radioimmunotherapy for low-grade, follicular, or transformed B- cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 39 (2001) 181-194
104. Wahl R.L., Kroll S., and Zasadny K.R. Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation. J Nucl Med 39 (1998) 14S-20S
105. Cremonesi M., Ferrari M., Chinol M., et al. Dosimetry in radionuclide therapies with Y-90-conjugates: the IEO experience. Q J Nucl Med 44 (2000) 325-332
106. Hindorf C., Chittenden S., Causer L., et al. Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors. Cancer Biother Radiopharm 22 (2007) 130-135
107. Barone R., Walrand S., Valkema R., et al. Correlation between acute red marrow (RM) toxicity and RM exposure during Y-90-SMT487 therapy. J Nucl Med 43 (2002) 1267
108. Esser J.P., Krenning E.P., Teunissen J.J.M., et al. TI Comparison of [Lu-177-DOTA(0), Tyr(3)] octreotate and [Lu-177- DOTA(0), Tyr(3)] octreotide: Which peptide is preferable for PRRT?. Eur J Nucl Med Mol Imaging 33 (2006) 1346-1351
109. Gotthardt M., van Eerd-Vismale J., Oyen W.J.G., et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 48 (2007) 596-601
110. EURATOM: Health protection of individuals against the dangers of ionising radiation in relation to medical exposure: Council directive 97/43 EURATOM, 1997
111. 131I outpatient therapy. J Nucl Med Technol 30 (2002) 165-171
112. Solans R., Bosch J.-A., Galofré P., et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 42 (2001) 738-743
113. Siegel J.A., Stabin M.G., and Brill A.B. The importance of patient-specific radiation dose calculations for the administration of radionuclides in therapy. Cell Mol Biol 48 (2002) 451-459
114. Thierens H.M., Monsieurs M.A., and Bacher K. Patient dosimetry in radionuclide therapy: The whys and the wherefores. Nucl Med Commun 26 (2005) 593-699 (review)
115. Robbins R.J., and Schlumberger M.J. The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med 46 (2005) 28S-37S